Our authors of the month conducted this retrospective case-control study in order to investigate the association of AD with the risk of COVID-19 infection (adjusted for comorbidities and sociodemographic factors).
Our paper of the month describes a study led by Stanford University researchers, which now provides a mechanistic basis for how EBV infection can trigger the patient’s immune cells to attack self-tissue within the CNS.
Our authors of the month conducted a longitudinal, multi-modal brain imaging study using the UK biobank, whereby participants had already been scanned before getting infected with SARS-CoV-2, offering a unique resource to elucidate these questions.
Our authors of the month conducted a systematic retrospective analysis of 150 lumbar punctures in 127 patients with PCR-proven COVID-19 and neurological symptoms seen at 17 European university centres.
The International Classification of Diseases 11 (ICD 11), maintained by the WHO and distributed globally, came into effect on 1 January 2022. The most notable change in the new set of classifications is that stroke has been reclassified as a neurological disorder, having previously been classed as a circulatory system disease for several decades.
Our authors of the month conducted a systematic review and meta-analysis in order to summarise the frequency of neurologic manifestations in patients with COVID-19 and to investigate the association of these manifestations with disease severity and mortality.
For February we have selected Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomized, placebo-controlled trial.
Our research paper of the month is a multicentre, randomised and double-blind phase 2 study with a futility design, exploring the efficacy and the safety of guanabenz in patients with probable or definite amyotrophic lateral sclerosis (ALS).